Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026
   Review
2. Infection prevention and control strategies for multidrug-resistant Gram-negative bacteria in healthcare: a narrative review.JAC-antimicrobial resistance · 2026
   Review
3. Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026
   Article
4. Early procalcitonin kinetics as an independent predictor of mortality in multi-drug resistant Klebsiella spp. bloodstream infections: a retrospective cohort study.BMC infectious diseases · 2026
   Observational
5. Epidemiology and carbapenemase gene distribution among carbapenem-resistant enterobacterales: a two-year retrospective study in a Saudi tertiary hospital.BMC microbiology · 2026
   Article
6. Carbapenem-resistant Enterobacterales bacteraemia at a tertiary hospital: A five-year review.Southern African journal of infectious diseases · 2026
   Article
7. Phenotypic, Targeted Genotypic, and Antimicrobial Susceptibility Profiling of Extended-Spectrum β-Lactamase Production and Exclusive blaJournal of clinical laboratory analysis · 2025
   Article
8. Epidemiology of carbapenem-resistant Enterobacterales infections in Tennessee, 2016-2022.Epidemiology and infection · 2025
   Article
9. Clinical and Economic Outcomes Associated with Complicated Urinary Tract Infections Caused by Carbapenem-resistantInfection & chemotherapy · 2025
   Article
10. Outcomes of Implementing a Multidimensional Antimicrobial Stewardship Program in a Medical Ward in a Third-Level University Hospital in Northern Italy.Antibiotics (Basel, Switzerland) · 2025
    Article
11. Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC infectious diseases · 2025
    Article
12. Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales.Antibiotics (Basel, Switzerland) · 2025
    Article
13. Epidemiology and outcomes of Carbapenem-resistant Enterobacterales infection in high-risk patients in Saudi Arabia.Frontiers in microbiology · 2025
    Article
14. A case-control study of the clinical and economic impact of infections caused by Carbapenemase-producing Enterobacterales (CPE).Infection · 2024
    Article
15. Efficacy and Safety of Oral Neomycin for the Decolonization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.